Sahlmann, Carsten-Oliver

[["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Lakhani, Vijai J."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Jung, Werner"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T11:14:10Z"],["dc.date.available","2018-11-07T11:14:10Z"],["dc.date.issued","2008"],["dc.format.extent","184"],["dc.identifier.isi","000256693500359"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54064"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.conference","10th International Conference on Malignant Lymphoma"],["dc.relation.eventlocation","Lugano, SWITZERLAND"],["dc.relation.issn","0923-7534"],["dc.title","Tandem HD-chemotherapy and myeloablative radioimmunotherapy with 131I-anti-CD20 rituximab in relapsed and refractory B-cell lymphoma: Final results of a phase II study of the German Rait Study Group"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","269"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Seminars in Dialysis"],["dc.bibliographiccitation.lastpage","276"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Becker, W."],["dc.date.accessioned","2018-11-07T10:24:06Z"],["dc.date.available","2018-11-07T10:24:06Z"],["dc.date.issued","2002"],["dc.description.abstract","Nuclear medicine (scintigraphy) studies that are performed in patients being prepared for regular dialysis treatment include the measurement of renal clearance and dynamic studies of renal perfusion and function. Static scintigraphy with 99mTc-DMSA may be used in the evaluation of children at risk of renal damage and further functional deterioration. In patients on peritoneal dialysis, nuclear medicine procedures enable the diagnosis of structural complications such as intra-abdominal herniations and leaks. Diagnosis of infections of the vascular access sites in patients on hemodialysis and of the catheter tunnel in patients on peritoneal dialysis can be made with high diagnostic accuracy using radiolabeled, autologous leukocytes. Scintigraphy is valuable in delineating the extent of deposits of amyloid and parenchymal microcalcifications, and may be helpful in the functional evaluation of organs and tissues involved in the pathophysiology of renal impairment and dialysis. If radioiodine therapy with I-131 is performed in patients on hemodialysis with benign or malignant thyroid disease, then pretherapeutic dosimetry is necessary to avoid over- and undertreatment. Radioiodine therapy in the dialysis patient leads to only insignificant contamination of dialysis equipment and marginal exposure to the medical staff."],["dc.identifier.doi","10.1046/j.1525-139x.2002.00069.x"],["dc.identifier.isi","000177597800008"],["dc.identifier.pmid","12191027"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42595"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing Inc"],["dc.relation.issn","0894-0959"],["dc.title","Nuclear medicine studies in the dialysis patient"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","223"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Nuklearmedizin"],["dc.bibliographiccitation.lastpage","227"],["dc.bibliographiccitation.volume","51"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Siggelkow, Heide"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Oezerden, M. M."],["dc.contributor.author","Braune, I."],["dc.contributor.author","Kluge, G."],["dc.contributor.author","Meller, Birgit"],["dc.date.accessioned","2018-11-07T09:14:40Z"],["dc.date.available","2018-11-07T09:14:40Z"],["dc.date.issued","2012"],["dc.description.abstract","The prevalence of cervical lymphadenopathy in autoimmune thyroiditis (AIT) patients is actually unknown. The aim of the study was the detailed retrospective evaluation of 6 index-patients with lymphadenopathy in Robbins level VI and a prospective study with high resolution ultrasound of lymphadenopathy in All patients compared with controls in all compartments of the neck, accessible to sonographic evaluation. Patients, methods: The retrospective study comprises six patients with AIT, evaluated for enlarged Robbins level VI-LN. We report the findings of fine-needle aspiration Cytology, clonal analysis, histology, and serological testing. The prospective study evaluated the prevalence of lymphadenopathy in 49 consecutive patients with AIT (group 1) and 49 consecutive patients with normal thyroids or nontoxic goiter (group2). Results: In the retrospective study, cytology of paratracheal LN revealed reactive lymphoid hyperplasia in 5/6 of the cases and a centroblastic lymphoma in one patient. The presence of monoclonal lymphatic cells was excluded in 5/6 patients and proven in 1/6 patients. Actual viral-infections were ruled out. In the prospective study All-patients showed significantly more enlarged LN in Robbins level II-IV and VI compared to controls. We found no correlation between lymphadenopathy, age, thyroid volume and nodularity, or autoantibody levels. During follow-up in 34 group 1-patients, lymphadenopathy remained stable in 28 patients, and decreased in 6 patients. Conclusion: Lymphadenopathy in Robbins level II-IV and VI is common in AIT-patients and most probably related to the autoimmune process."],["dc.identifier.doi","10.3413/Nukmed-0484-12-03"],["dc.identifier.isi","000312613800004"],["dc.identifier.pmid","23042429"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27472"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Schattauer Gmbh-verlag Medizin Naturwissenschaften"],["dc.relation.issn","0029-5566"],["dc.title","Patients with autoimmune thyroiditis Prevalence of benign lymphadenopathy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Nuclear Medicine"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Altenvoerde, G."],["dc.contributor.author","Lehmann, K."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Behe, E."],["dc.contributor.author","Becker, W."],["dc.date.accessioned","2018-11-07T09:07:39Z"],["dc.date.available","2018-11-07T09:07:39Z"],["dc.date.issued","2001"],["dc.format.extent","332P"],["dc.identifier.isi","000168821901274"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25849"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Soc Nuclear Medicine Inc"],["dc.publisher.place","Reston"],["dc.relation.issn","0161-5505"],["dc.title","Fever of unknown origin - Prospective comparison of FDG-imaging with a double head coincidence camera (DHCC) and Ga-67-citrate SPECT."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Goldenberg, David M."],["dc.date.accessioned","2018-11-07T11:15:03Z"],["dc.date.available","2018-11-07T11:15:03Z"],["dc.date.issued","2008"],["dc.identifier.isi","000208457401598"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54282"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.issn","0732-183X"],["dc.title","Repeated anti-CEA-radioimmunotherapy (RAIT) with 131iodine-labetuzumab (phase II study) versus single dose RAIT after salvage resection of colorectal liver metastases (CRC-LM)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1307"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1315"],["dc.bibliographiccitation.volume","90"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Sahlmann, Carsten Oliver"],["dc.contributor.author","Lakhani, Vijai J."],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T08:50:15Z"],["dc.date.available","2018-11-07T08:50:15Z"],["dc.date.issued","2011"],["dc.description.abstract","A phase II trial evaluated safety, feasibility and efficacy of a sequential tandem approach combining myeloablative BEAM chemotherapy and autologous stem cell transplantation (ASCT) with myeloablative radioimmunotherapy (HD-RIT), with I-131-anti-CD20 antibody (I-131-rituximab), followed by a second ASCT in patients with relapsed or refractory CD20+ B-cell lymphoma. According to protocol, 16 patients with relapsed (n=14) and refractory (n=2) CD20+ B-cell lymphoma received salvage therapy with rituximab and Dexa-BEAM, followed by BEAM (HD chemotherapy) and high-dose myeloablative radioimmunotherapy 2-6 months after BEAM. Nine of 16 patients received HD-RIT; seven patients were excluded before HD-RIT because of toxicity or progressive disease. Disease histologies were follicular lymphoma (FL) grades 1 and 2 (n=4), transformed follicular (FL 3b; n=6), diffuse large B-cell (DLBCL; n=4), mantle cell (n=1) and marginal zone lymphoma (n=1). After a median follow-up of 50.4 months for OS and 39.7 months for progression-free survival (PFS), estimated 4-year OS and PFS were 67% and 64%, respectively. The estimated 4-year OS and PFS for patients with FL were 80% and 78%, respectively. Toxicity was significant, including one fatal outcome due to pneumonitis. Tandem transplants consisting of HD chemotherapy followed by HD-RIT with I-131-coupled anti-CD20 are manageable and effective but toxic treatment modalities for relapsed poor prognosis CD20+ B-NHL."],["dc.identifier.doi","10.1007/s00277-011-1199-y"],["dc.identifier.isi","000296730300008"],["dc.identifier.pmid","21360108"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7836"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21653"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with I-131-anti-CD20 antibody and stem cell rescue"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","66"],["dc.bibliographiccitation.journal","EJNMMI Research"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Hijazi, Sameh"],["dc.contributor.author","Bouter, Caroline"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Thelen, Paul"],["dc.date.accessioned","2018-11-07T09:48:52Z"],["dc.date.available","2018-11-07T09:48:52Z"],["dc.date.issued","2015"],["dc.description.abstract","Background: Prostate-specific membrane antigen (PSMA) is a promising target for diagnostics and therapy of prostate carcinoma (PCa). Based on the hypothesis that PSMA expression can be modulated by variations in androgen deprivation therapy (ADT), we investigated the binding of a PSMA-directed radiopharmaceutical in vitro in order to get an insight of the interactions between altered premedication and PSMA expression before repetitive PSMA-directed PET/CT for therapy response and targeted therapy implementation. Methods: The human castration-resistant PCa cell line VCaP (CRPC) was treated with either 1 nmol/L testosterone (T) over 20 passages yielding the androgen-sensitive cell line (revCRPC) or with 5 mu mol/L abiraterone acetate (AA) generating the abiraterone-tolerant subtype CRPCAA. In these cell lines, T and AA were varied by either supply or withdrawal of T and AA. PSMA expression of the three cell culture models was detected by Western blot and immunohistochemical staining. For quantitative measurement of tracer uptake, 0.3 nmol/L Ga-68-labelled PSMA-HBED-CC peptide (100-300 kBq/ml) was added to different treated parallel cultures (n = 9 each). Time-dependent uptake per 10(6) cells of each culture was calculated and evaluated. PSMA mRNA expression was investigated by qPCR. Results: PSMA expression increased dependently on intensified ADT in all three basic cell lines. Ga-68-PSMA-HBED-CC uptake almost doubled during 3 h in all cell lines (p < 0.01). Compared to the basic cells, pre-incubation with abiraterone for 48 h resulted in a significant increased uptake in CRPC (p < 0.001). In revCRPC, 48-h AA pre-incubation resulted in an eightfold higher uptake after 3 h (p < 0.001). Additional withdrawal of external testosterone increased the uptake up to tenfold (p < 0.01). The increase of PSMA expression upon ADT and AA treatments was confirmed by qPCR and Western blot data. Furthermore, in CRPCAA, 48-h AA withdrawal increased the uptake up to fivefold (p < 0.01). Conclusions: The investigated three PCa cell culture subtypes represent a serial preclinical model of androgen deprivation therapy as a proxy for clinical situations with differing basal PSMA expression. The uptake of PSMA-binding tracers could be stimulated by therapeutic effective short-term variation in premedication in all stages of ADT response. These complex interactions have to be considered in the interpretation of diagnostic imaging using PSMA ligands as well as in the optimal timing of PSMA-based therapies."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft DFG [TH 389/3-1, BR4700/1-1]"],["dc.identifier.doi","10.1186/s13550-015-0145-8"],["dc.identifier.isi","000364963600001"],["dc.identifier.pmid","26576996"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12584"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35393"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","2191-219X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","22"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Nuklearmedizin"],["dc.bibliographiccitation.lastpage","29"],["dc.bibliographiccitation.volume","41"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Lehmann, K."],["dc.contributor.author","Siefker, U."],["dc.contributor.author","Meyer, I."],["dc.contributor.author","Schreiber, K."],["dc.contributor.author","Altenvoerde, G."],["dc.contributor.author","Becker, W."],["dc.date.accessioned","2018-11-07T10:32:22Z"],["dc.date.available","2018-11-07T10:32:22Z"],["dc.date.issued","2002"],["dc.description.abstract","Aim: Evaluation of F-18-FDG-hybrid-camera-PET imaging in patients with undetermined postoperative fever (POF). Methods: Prospective study of 18 patients (9 women, 9 men; age 23-85 years) suffering from POF with 2-fluoro-2'-deoxyglucose (F-18-FDG) using a dual headed coincidence camera (DHCC). Surgery had been performed 5-94 days prior to our investigation. 13 of the 18 patients received antibiotic therapy during the time of evaluation. Ton (55%) had an infectious and eight (45%) a non infectious cause of fever. Results: Increased F-18-FDG-uptake outside the surgical wound occurred in 13 regions (infection n = 11, malignancy n = 2). The sensitivity of F-18-FDG-hybrid-camera-PET in imaging infection in areas outside the surgical wound was 86% and the specificity 100%, respectively. Antibiotic therapy did not negatively influence the results of F-18-FDG-scanning. Increased F-18-FDG-uptake within the surgical wound was seen in 8 of 18 patients. The sensitivity of F-18-FDG-hybrid-camera-PET in imaging infection within the surgical wound was 100% and the specificity 56%, respectively. The interval between surgery and F-18-FDG-scanning was significantly shorter in patients with false positive results compared with patients showing true negative results (median 34 vs. 54 days; p = 0,038). Conclusion: In POF-Patients, F-18-FDG transaxial tomography performed with a F-18-FDG-hybrid-camera-PET is sensitive in the diagnosis of inflammation and malignant disease within and outside the surgical wound. Because of the accumulation of the tracer both in granulation tissue and infection, the specificity in detecting the focus of fever within the surgical wound is poor."],["dc.identifier.isi","000174205500004"],["dc.identifier.pmid","11917344"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44329"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Schattauer Gmbh-verlag Medizin Naturwissenschaften"],["dc.relation.issn","0029-5566"],["dc.title","F-18-FDG-hybrid-camera-PET in patients with postoperative fever"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Jung, Werner"],["dc.contributor.author","Stitz, E."],["dc.contributor.author","Meller, J."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T10:18:39Z"],["dc.date.available","2018-11-07T10:18:39Z"],["dc.date.issued","2005"],["dc.format.extent","135"],["dc.identifier.isi","000233670100335"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41490"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.conference","9th International Conference on Malignant Lymphoma"],["dc.relation.eventlocation","Lugano, SWITZERLAND"],["dc.relation.issn","0923-7534"],["dc.title","Tandem high dose chemotherapy and myeloablative radioimmunotherapy with 131-I-anti-CD20 rituximab in relapsed and refractory B-cell lymphoma: Interim results of a phase II study of the German RIT study group"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","242"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Nuklearmedizin"],["dc.bibliographiccitation.lastpage","249"],["dc.bibliographiccitation.volume","55"],["dc.contributor.author","Bouter, Caroline"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Sahlmann, Carsten"],["dc.contributor.author","Ritter, Carsten"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Braune, Isabell"],["dc.date.accessioned","2018-11-07T10:19:48Z"],["dc.date.available","2018-11-07T10:19:48Z"],["dc.date.issued","2016"],["dc.description.abstract","The diagnostic strategy in patients with fever or inflammation of unknown origin remains a major clinical challenge. The aim of this study was to evaluate the role of F-18-FDG-PET/CT in patients with unexplained elevated C-reactive protein with or without fever. Contribution of F-18-FDG-PET/CT to the final diagnosis was evaluated. In addition we determined whether a differentiation between patients with or without fever is clinically reasonable. Patients, methods: We retrospectively analysed 72 consecutive patients with unexplained elevated C-reactive protein levels (above 8mg/l) that underwent F-18-FDG-PET/ CT in our facility between 10/2009 and 11/2012. 18F-FDG-PET/CT was considered a so-called diagnostic scan when results decisively led to a final diagnosis and adequate therapy with a response of symptoms was initiated due to the PET/CT result. Results: In 60/72 patients (83%) a final diagnosis was established. Diagnoses included infections (58%), non-infectious inflammatory diseases (29%) and malignancies (8%). F-18-FDG-PET/CT was true positive in 47 cases (65%) and the diagnostic scan in 29 patients (40%). Sensitivity of 18F-FDG-PET/CT was 81% and specificity was 86%. Diagnostics, final diagnoses, F-18-FDG-PET/CT results, SUVmax, C-reactive protein levels and the diagnostic scan did not differ significantly between patients with fever and patients without fever. Conclusion: F-18-FDG-PET/CT is a useful method in the diagnostic workup of patients with inflammation of unknown origin. In our series there was no significant difference between patients with or without fever. Regarding F-18-FDG-PET/CTimaging inflammation of unknown origin and unexplained fever can be joined to one entity."],["dc.identifier.doi","10.3413/Nukmed-0798-16-02"],["dc.identifier.eissn","2567-6407"],["dc.identifier.isi","000389621900006"],["dc.identifier.issn","0029-5566"],["dc.identifier.pmid","27617327"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41740"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0029-5566"],["dc.title","F-18-FDG-PET/CT in unexplained elevated inflammatory markers"],["dc.title.alternative","Joining entities"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]